Safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in patients with HCV genotype 1 and 4 infection-fnal data from the real-world AMBer study

Authors
Category Primary study
JournalClinical and Experimental Hepatology
Year 2016
This article has no abstract
Epistemonikos ID: 198a4d250dfffd8a987ed9efe840267e6a035012
First added on: Feb 08, 2025